Monica Marta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5012216/publications.pdf

Version: 2024-02-01

62 papers	3,282 citations	304602 22 h-index	149623 56 g-index
82 all docs	82 docs citations	82 times ranked	4612 citing authors

#	Article	IF	Citations
1	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Multiple Sclerosis and Related Disorders, 2022, 57, 103409.	0.9	1
2	Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A2.3-A2.	0.9	0
3	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. Aids, 2021, 35, 2341-2346.	1.0	8
4	Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2021, 56, 103284.	0.9	1
5	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	1.5	5
6	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ Open, 2021, 11, e050176.	0.8	3
7	Inclusion criteria used in trials of people with progressive multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 279-283.	1.4	3
8	CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e880.	3.1	12
9	Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093616.	1.5	58
10	Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences, 2020, 417, 117079.	0.3	10
11	Cognitive and Neurologic Rehabilitation Strategies for Central Nervous System HIV Infection. Current HIV/AIDS Reports, 2020, 17, 514-521.	1.1	10
12	The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.. Multiple Sclerosis and Related Disorders, 2020, 44, 102279.	0.9	77
13	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 102024.	0.9	6
14	Protecting people with multiple sclerosis through vaccination. Practical Neurology, 2020, 20, 435.1-445.	0.5	40
15	No evidence of disease activity in people with multiple sclerosis. European Journal of Neurology, 2019, 26, 1-2.	1.7	1
16	Visibility and representation of women in multiple sclerosis research. Neurology, 2019, 92, 713-719.	1.5	13
17	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders, 2019, 27, 247-253.	0.9	10
18	Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology, 2018, 154, 253-260.	2.0	32

#	Article	IF	Citations
19	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders, 2018, 24, 123-128.	0.9	25
20	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878376.	0.5	7
21	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine, 2017, 16, 41-50.	2.7	225
22	Disease modification in advanced MS: Focus on upper limb function. Multiple Sclerosis Journal, 2017, 23, 1956-1957.	1.4	8
23	Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Multiple Sclerosis and Related Disorders, 2017, 17, 172-176.	0.9	6
24	PO124â€...Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A44.3-A45.	0.9	0
25	PO134â€...Personalised dosing of cladribine to treat multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A47.4-A48.	0.9	1
26	PO150â€...Memory b cells are key for immunotherapy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A52.2-A52.	0.9	0
27	Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy. Aids, 2016, 30, 1143-1144.	1.0	4
28	Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurology, 2016, 16, 389-393.	0.5	39
29	IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. Practical Neurology, 2016, 16, 235-239.	0.5	9
30	Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2015, 4, 329-333.	0.9	275
31	Deep Sequencing of HIV-1 in Cerebrospinal Fluid: Table 1.. Clinical Infectious Diseases, 2015, 61, 1022-1025.	2.9	12
32	Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e74.	3.1	2
33	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
34	Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. Multiple Sclerosis and Related Disorders, 2015, 4, 88-91.	0.9	4
35	The role of infections in BehÃ§et disease and neuro-BehÃ§et syndrome. Autoimmunity Reviews, 2015, 14, 609-615.	2.5	18
36	No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e158.	3.1	109

#	Article	IF	Citations
37	Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurology, 2014, 14, 237.	0.8	11
38	Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats. Neurobiology of Disease, 2014, 71, 220-233.	2.1	34
39	Anti-MOG antibodies are under polygenic regulation with the most significant control coming from the C-type lectin-like gene locus. Genes and Immunity, 2013, 14, 409-419.	2.2	11
40	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS â€“ Neurofilament as a Surrogate of Disease Progression. PLoS ONE, 2013, 8, e70019.	1.1	48
41	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.5	177
42	Development of resistance to biologic therapies with reference to IFN-Â. Rheumatology, 2012, 51, 590-599.	0.9	22
43	Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon. CNS and Neurological Disorders - Drug Targets, 2012, 11, 610-623.	0.8	29
44	A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology, 2011, 77, 1551-1560.	1.5	118
45	Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. Pathophysiology, 2011, 18, 13-20.	1.0	19
46	Vitamin D deficiencyâ€“do we follow our own advice?. Clinical Medicine, 2011, 11, 521-523.	0.8	0
47	Epsteinâ€“Barr Virus and Multiple Sclerosis. , 2011, , 25-37.		1
48	Multiple loci comprising immune-related genes regulate experimental neuroinflammation. Genes and Immunity, 2010, 11, 21-36.	2.2	20
49	Fine-Mapping Resolves Eae23 into Two QTLs and Implicates ZEB1 as a Candidate Gene Regulating Experimental Neuroinflammation in Rat. PLoS ONE, 2010, 5, e12716.	1.1	23
50	TNF Production in Macrophages Is Genetically Determined and Regulates Inflammatory Disease in Rats. Journal of Immunology, 2010, 185, 442-450.	0.4	14
51	Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-BarrÃ© Syndrome. Journal of Immunology, 2009, 182, 4432-4438.	0.4	18
52	Tollâ€like Receptors in Multiple Sclerosis Mouse Experimental Models. Annals of the New York Academy of Sciences, 2009, 1173, 458-462.	1.8	53
53	Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmunity Reviews, 2009, 8, 506-509.	2.5	69
54	Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2008, 38, 565-575.	1.6	180

#	Article	IF	Citations
55	Profound and paradoxical impact on arthritis and autoimmunity of the rat antigenâ€presenting lectinâ€like receptor complex. Arthritis and Rheumatism, 2008, 58, 1343-1353.	6.7	15
56	The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. Journal of the Neurological Sciences, 2007, 258, 69-74.	0.3	39
57	Hypersomnia in Whipple disease: case report. Arquivos De Neuro-Psiquiatria, 2006, 64, 865-868.	0.3	11
58	Eae19, a New Locus on Rat Chromosome 15 Regulating Experimental Autoimmune Encephalomyelitis. Genetics, 2005, 170, 283-289.	1.2	13
59	Resolution of a 16.8-Mb Autoimmunity-Regulating Rat Chromosome 4 Region into Multiple Encephalomyelitis Quantitative Trait Loci and Evidence for Epistasis. Journal of Immunology, 2005, 174, 918-924.	0.4	24
60	Multiple Sclerosis Severity Score. Neurology, 2005, 64, 1144-1151.	1.5	836
61	T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis. Journal of Immunology, 2004, 172, 7169-7176.	0.4	200
62	A whole genome association study in multiple sclerosis patients from north Portugal. Journal of Neuroimmunology, 2003, 143, 116-119.	1.1	13